<DOC>
	<DOCNO>NCT00091338</DOCNO>
	<brief_summary>RATIONALE : Interleukin-7 may stimulate person 's white blood cell kill tumor cell . Vaccines make peptide may make body build immune response kill tumor cell . Combining interleukin-7 vaccine therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose interleukin-7 give vaccine therapy treat patient metastatic melanoma .</brief_summary>
	<brief_title>Interleukin-7 Vaccine Therapy Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose interleukin-7 ( IL-7 ) administer melanoma peptide vaccine emulsify Montanide ISA-51 patient metastatic melanoma . - Determine safety regimen patient . Secondary - Determine biological effect regimen T-cell function phenotype various dos optimal biological dose patient . - Determine pharmacokinetic pharmacodynamic characteristic IL-7 patient treat regimen . - Determine antitumor effect IL-7 , term dose-escalation strategy , patient . OUTLINE : This dose-escalation study interleukin-7 ( IL-7 ) . Patients receive IL-7 subcutaneously ( SC ) day 0 , 3 , 6 , 9 , 12 , 15 , 18 , 21 . Patients also receive melanoma peptide vaccine comprise gp100 antigen MART-1 antigen emulsify Montanide ISA-51 SC day 0 , 7 , 14 , 21 absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos IL-7 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After MTD determine , additional 13 patient treat dose level . Patients follow 1 , 2 , 5 week , 3 6 month , 1 year . PROJECTED ACCRUAL : A total 3-37 patient accrue study within 1-12.3 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma Metastatic disease Measurable evaluable disease Disease progression prior interleukin2 ( IL2 ) OR ineligible receive highdose IL2* OR disease burden IL2 indicated* NOTE : *If patient receive prior IL2 , must progress prior standard firstline therapy ( e.g. , metastasectomy single lesion dacarbazine ) HLAA*0201positive disease PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3* Absolute lymphocyte count ≥ 200/mm^3* Platelet count &gt; 100,000/mm^3 No proliferative hematologic disease NOTE : *For 2 consecutive reading perform 2 different day Hepatic AST ALT &lt; 3 time upper limit normal ( ULN ) PT/PTT ≤ 1.5 time ULN Hepatitis B negative Positive hepatitis B serology indicative prior immunization ( i.e. , positive antibody hepatitis B surface antigen AND negative antibody hepatitis B core antigen ) allow Hepatitis C negative Renal Creatinine ≤ 1.4 mg/dL Cardiovascular Ejection fraction &gt; 45 % MUGA patient ≥ 50 year age OR history cardiac disease No rest blood pressure &gt; 140/90 mm Hg standard antihypertensive therapy Pulmonary DLCO/VA FEV_1 &gt; 50 % predict pulmonary function test smoker OR patient clinical evidence compromise pulmonary function No history severe asthma Immunologic HIV negative No history autoimmune disease No splenomegaly Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No medical psychiatric disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics More 4 week since prior cytokine No prior allogeneic hematopoietic stem cell transplantation No concurrent growth factor No concurrent monoclonal antibody No concurrent immunotherapy No concurrent cytokines No concurrent biologic agent Chemotherapy See Disease Characteristics No prior intensive myeloablative chemotherapy No concurrent chemotherapy Endocrine therapy More 2 week since prior systemic corticosteroid 72 hour duration No concurrent systemic steroid Radiotherapy Not specify Surgery See Disease Characteristics No prior splenectomy No prior solid organ transplantation Other More 4 week since prior cytotoxic therapy No concurrent cytotoxic therapy No concurrent chronic anticoagulation therapy ( e.g. , highdose warfarin , heparin , aspirin ) Concurrent lowdose warfarin ( 12 mg ) allow No concurrent chronic medication asthma No concurrent immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>